Page 49 - Livre électronique du congrès national de pneumologie 2017

XXII è me Congrès National de Pneumologie. Tunis 14-16 Décembre 2017

Références :

1. Chew H, Wun T, Harvey D et al. Incidence of venous thromboembolism and its effect on survival
among patients with common cancers. Arch Intern Med 2006; 166(4):458-64.

2. Milsom C, Yu J, Mackman N et al. Tissue Factor regulation by Epidermal Growth Factor Receptor and
epithelial-to mesenchymal transitions: Effect on tumor initiation and angiogenesis. Cancer Res
2008;68:10068-76
3. Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous
thromboembolism. N Eng J Med 2000; 343 (25): 1846-50

4. Gary T, Belaj K, Steidl K, Pichler M. Asymptomatic deep vein thrombosis in ambulatory cancer patients:
impact on short-term survival. Br J Cancer 2012; 107, 1244-48

5. Prandoni P, Lensing AW, Piccioli A, Bernardi E. Recurrent venous thromboembolism and bleeding
complications during anticoagulation treatment in patients with cancers and venous thrombosis.
Blood 2002; 100: 3484-8

6. Mandala M, Falanga A, Roila F. Management of venous thromboembolism in cancer patients. ESMO
clinical practice guidelines. Annals of Oncology. Sept 2011. Vol 22, Issue suppl-6, vi 85-vi92
7. Farge D, Debourdeau P, Becjers M, Baglin C. International clinical practice guidelines for the treatment
and prophylaxis of VTE in patients with cancer. J Thromb Haemost 2013 Jan; 11(1): 56-70

8. Kearon C, Akl EA, Ornelas J, Blaivas A. Antithrombotic therapy for VTE disease: Chest guideline and
expert panel report. Chest 2016 Feb. 149(2): 315-352

9. Raskob GE, Van ES N, Segers A, Angchiaisusksiri P. Endoxaban for VTE in patients with cancer:
Results from a non-inferiority subgroup analysis of the Hokusai VTE randomized double-blind double-
dummy trial. Lancet Haematol 2016 Aug; 3(8): e379-87

10. Wiener RS, Schwartz LM, Woloshin S. When a test is too good: how CT pulmonary angiograms find
pulmonary emboli that do not need to be found. BMJ. 2013;347

11. Klok FA, Huisman MV. Management of incidental pulmonary embolism. ERJ. 2017; 49 (6)
12. Carrier M, Righini M, Le Gal G. Symptomatic subsegmental pulmonary embolism: what is the next
step. J Thromb Haemost. 2012; 10 (8): 1486-90

13. Van der Huile T, Den Exter PL, Meyer G et al. Risk of recurrent venous thromboembolism and major
bleeding in cancer associated incidental pulmonary embolism amongst treated and untreated patients:
a pooled analysis of 926 patients. Blood. 2014; 124: 590
14. Di Nisio M, Lee AYY, Carrier M et al. Diagnosis and treatment of incidental venous thromboembolismin
cancer patients. Guidance from the SCC of the ISTH. J Thromb Haemost 2015; 13: 880-883

15. Donellan E, Khorana A. Cancer and venous thromboembolic disease: A review. The Oncologist 2017;
22: 199-207

44